Company: PFSA
Filing Date: 2025-09-17
Form Type: S-1/A
Source: 0001213900-25-088333
Chunk: 328

Company: Profusa, Inc.
Filing Date: 2025-09-17
Form: S-1/A
Chunk 328
---
 of the initial Business Combination in an amount of 3.68% of the gross proceeds of the IPO, or $ 6,986,250. The agreement was amended on November 7, 2022 to allow for the 3.68% business combination fee to be paid as (a) 27.5% cash and (b) 72.5% to be rolled into equity at closing. Subsequently, on January19, 2025, the agreement was modified by the parties such that the Company will be required to pay $ 2,000,000, payable in cash, if a business combination is consummated. Representative’s Shares On December 22, 2021, the Company issued 450,000shares (Representative Shares) of common stock (which included 37,500Representative Shares issued pursuant to the full exercise of the over -allotmentoption) at the consummation of the IPO to I -Bankersand Dawson James (and/or their designees). I -Bankersand Dawson James (and/or their designees) have agreed not to transfer, assign or sell any such shares until the completion of the initial Business Combination. In addition, I -Bankersand Dawson James (and/or their designees) have agreed (i) to waive their F-73 NORTHVIEW ACQUISITION CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Note 6 — Commitments and Contingencies (cont.) redemption rights with respect to such shares in connection with the completion of the initial Business Combination and (ii) to waive their rights to liquidating distributions from the Trust Account with respect to such shares if the Company fails to complete its initial Business Combination within the Combination Period. The fair value of the Representative’s Shares issued are recognized as offering costs directly attributable to the issuance of an equity contract to be classified in equity and are recorded as a reduction of equity (see Note 1). Representative’s Warrants The Company granted to I -Bankersand Dawson James (and/or their designees) 569,250warrants (which included 74,250warrants issued pursuant to the full exercise of the over -allotmentoption) exercisable at $ 11.50per share (or an aggregate exercise price of $ 6,546,375) at the closing of the IPO. The Representative Warrants issued are recognized as derivative liabilities in accordance with ASC 815 -40and recorded as liabilities at fair value each reporting period (